NOVEL PEPTIDE-INHIBITOR PI3Kγ FOR TREATING RESPIRATORY DISEASES Russian patent published in 2019 - IPC C07K14/47 A61K38/17 C12N9/12 A61K45/06 A61P11/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to biotechnology and medicine, specifically to a novel peptide inhibitor PI3Kγ for treating respiratory pathologies. Disclosed are a fusion peptide which inhibits the PI3Kγ kinase-independent function, a combined preparation for sequential, simultaneous or separate application for treating broncho-obstructive diseases and a pharmaceutical composition for treating respiratory diseases. Peptide contains i) amino acid sequence SEQ ID No. 1 or a related homologue having at least 90 % identity with SEQ ID No. 1 and having the ability to inhibit the PI3Kγ kinase-independent function, and ii) a peptide capable of penetrating into the cell. Combined preparation contains a fused peptide and a potential regulator of transmembrane conductivity in cystic fibrosis (CFTR) and/or a corrector of a transmembrane conductance regulator in cystic fibrosis (CFTR). Pharmaceutical composition contains at least one fused peptide or a combined preparation. Disclosed fusion peptide is therapeutically effective.

EFFECT: aerosol composition of inhibitory peptide PI3Kγ is effectively distributed in the lower respiratory tract and is suitable for treating respiratory diseases selected from allergic asthma, cystic fibrosis and chronic obstructive pulmonary disease.

9 cl, 7 dwg